Bilobalide injection and content determination method

A technology of ginkgolide and determination method, which is applied in the field of detection method and content determination of ginkgolide injection, and can solve problems such as non-formation, inability to guarantee clinical efficacy and safety, uncertain composition ratio of ginkgolide, etc.
CN103239487AActive Publication Date: 2013-08-14CHENGDU BAIYU PHARMA CO LTD
4 Cites 7 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
CHENGDU BAIYU PHARMA CO LTD
Publication Date
2013-08-14

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention relates to the field of plant extraction and in particular relates to a method for detecting bilobalide injection for treating cardiovascular and cerebrovascular diseases and a method for determining content of active ingredients. The content of ginkgo terpene lactone in every 1ml of the determined bilobalide injection is 1-10mg / ml based on the total amount of bilobalide (C15H18O8), ginkgolides A (C20H24O9), ginkgolides B (C20H24O10) and ginkgolides C (C20H24O11), and preferably 4.25-5.75mg.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to the field of plant extraction, in particular to a detection method and content determination method of ginkgolide injection for treating cardiovascular and cerebrovascular diseases. Background technique

[0002] Since the 1960s, many countries have used modern separation techniques to study the chemical components of Ginkgo biloba. Through pharmacological experiments and clinical verification, it has been found that the various biological activities of Ginkgo biloba are related to the specific chemical components contained in them. Dr.Willar Schwabe of Germany registered a simple extract of Ginkgo biloba for the first time, and applied for a patent in 1972 (W Schwabe DE176708 and DE2117429), named EGb761, for the treatment of cardiovascular and cerebrovascular diseases and nervous system diseases, with significant curative effect , and no toxic side effects, ginkgolides (ginkgolids) have strong platelet activating factor (PAF) ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More